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Introduction
Mesoporous silica nanoparticles (MSNs) have attracted the 
attention of several scientists over the last decade due to their potential 
applications. Among the main features of mesoporous materials is the 
high surface area, pore volume and the highly ordered pore network 
which is very homogeneous in size. As a result of these features 
MSNs are excellent candidates as drug delivery systems. MSNs can 
be synthesized either by an alkaline route [1] or an acid route [2] 
both using surfactants as templates. Under alkaline conditions the 
silica precursors are negatively charged and they interact with the 
positively charged surfactants via electrostatic interactions. #e silica 
species therefore polymerize at the micelle surface, thereby creating 
a negatively charged silica surface. Subsequently, surfactants are self–
assembled into the structure that best matches the silica surface. By 
removing the surfactants an ordered stable, porous structure with high 
surface area is created.
Initially, MSNs were discovered by Mobil scientists [1,3] designated 
as MCM–41 or MCM–48 and used as molecular sieves. However, for 
$rst time MSNs were used as drug delivery system by Valet–Regi [4] 
to encapsulate Ibuprofen in MCM–41 of various pore sizes. In several 
occasions MSNs have been reported to control the release pro$le or 
to enhance the solubility of various active substances [5,8]. #e MSNs 
pore size can be designed slightly larger than the dimension of the drug 
molecule and thus to provide sustained release for several hours [9]. In 
addition, MSN present high drug loading capacities ranging from 10 
to 34% [10] or even to 60% in rare cases [11].#e presence of surface 
silanol groups facilitates MSN’s functionalization [12,14] by various 
groups (hydroxyl, amine, thiol, carboxyl) which can then conjugated 
with "uorophores and target ligands for optical imaging of tumour 
cells in vitro. MSNs have been also used as drug delivery systems of 
both water insoluble [15] and water soluble anticancer agents [16] by 
providing controlled release in the cell compartments. 
In the current study we investigated the encapsulation of 
carbamazepine (CBZ) in MCM–41 nanoparticles by using supercritical 
CO
2
 processing. #e CO
2
 process has been previously employed to 
load silica aerogels [17–20]. Initially, Smirnova et al. (2004) reported 
that CO
2
 was successfully used to load various active substances in 
hydrophilic and hydrophobic aerogels leading to increased loading 
e&ciencies. In later studies, the same group investigated the adsorption 
of various organic molecules as a function of crystallization, surface 
properties and surface interactions. Nowadays, about 40% of small–
molecule drugs in the pipeline of the pharmaceutical companies present 
low water solubility [21,22] and therefore it is di&cult to formulate. 
Carbamazepine is a major antilepileptic pharmacological agent with 
low water solubility (13mg/100mL) and its inclusion in MCM–41 is 
expected to increase dissolution rates. Currently, drug loading of 
MSNs is conducted by using various approaches such as solvent, 
incipient wetness impregnation and melt methods to enhance drug 
loading in pore channels [23]. Herein, supercritical "uid processing is 
introduced as a reproducible, controllable and scalable alternative for 
drug loading. In addition, we report the e*ect of CO
2
 processing on the 
crystallinity of the active substance and how this could induce changes 
on the polymorphic CBZ forms. 
Materials and Methods
Materials
Carbamazepine was kindly donated by Novartis Pharma 
(Basel, Switzerland). Tetraethyl Orthosilicate (TEOS) and 
hexadecyltrimethylammonium bromide (CTAB) were obtained from 
Sigma Aldrich (St. Lewis, US). #e HPLC grade solvents acetone, 
methanol, ethanol were purchased from Fisher Chemicals (Karlsruhe, 
UK). All materials were used as received.
Synthesis of mesoporous silica nanoparticles
CTAB (0.5g) 2.0M NaOH (1.75ml) and deionised water (120g) 
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Abstract
Mesoporous silica nanoparticles MCM – 41 were synthesized with two dimensional hexagonal p6mm symmetry, 
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nanoparticles were used to encapsulate carbamazepine through a supercritical carbon dioxide process combined 
with various organic solvents. Supercritical processing was found to provide increased drug encapsulation. The 
loaded MCM - 41 nanoparticles were analyzed using X–ray diffraction and differential scanning calorimetry (DSC) to 
investigate the crystalline state of the encapsulated carbamazepine and it was found to be dependent on the nature 
of the organic solvent. Carbamazepine showed increased dissolution rates under sink conditions. Viability studies of 
Caco – 2 cells demonstrated negligible cytotoxicity for the MCM–41 nanoparticles. 
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were heated at 80°C for 30 minutes to reach a PH of 12.3 To this clear 
solution TEOS (2.34gm) 2.5ml is rapidly injected via injection under 
vigorous stirring. Following the injection a white precipitation will 
be observed within three minutes of stirring at 550 rpm. #e reaction 
temperature is maintained at 80°C for 2 hours. #e product is isolated 
by hot $ltration washed with copious amount of water and methanol 
(5ml each for three times). An acid extraction was performed in a 
methanol (100 mL) mixture of concentrated hydrochloric acid (1.0 mL) 
and as-made materials (1.0 g) at 60C for 6 h. #e surfactant-removed 
solid products were $ltered and washed with water and methanol, and 
then dried under vacuum.
Drug encapsulation
#e process used for the CBZ encapsulation in mesoporous silica 
nanoparticles was conducted in a high pressure R250 CW reactor (#ar 
Technologies Inc. USA). CBZ was dissolved in various organic solvents 
following mixing with supercritical CO
2
 into the high pressure vessel to 
reach the operating conditions of pressure (150 bars) and temperature 
(70°C). #e contents of the vessel were then mixed with a paddle stirrer 
for 1 hr under the operating conditions before decompression of the 
vessel and removal of the drug encapsulated nanoparticles. A:er a 
1 hr decompression cycle the organic solvent "ushed out by feeding 
CO
2
 simultaneously. Figure 1 depicts a schematic diagram of the high 
pressure reactor. 
Determination of loading e"ciency
#e loading e&ciency of MCM–41 was determined by adding 50 
mg of loaded samples in 20 ml ACN and stirred for 24 hr. #e samples 
were centrifuged in a Sorval RC6 Plus centrifuge at 7000 rpm for 
30 min. #e supernatant was collected and determined with HPLC 
analysis.
Particle size measurements
#e particle size of the dispersions was measured with Malvern 
Masterisizer 2000 (Malvern, UK) combining information from simple 
light scattering (LS) and polarization intensity di*erential scattering 
(PIDS). For data evaluation, an optical model based on the Mie theory 
was created using the instrumental so:ware assuming 1.45 as the real 
and 0 as the imaginary part of the refractive index of the particles. 
Results given are the mean of 5 successive measurements of 120 s each.
Scanning Electron Microscopy (SEM)
#e morphology of newly synthesized MCM–41 was examined by 
scanning electron microscopy. #e samples were attached to aluminum 
stubs with double side adhesive carbon tape then gold coated and 
examined using a scanning electron microscope (Jeol 5200, SEM).
Transmission Electron Microscopy (TEM)
TEM carried out with a JEOL JSM200CX operating at 200kV 
accelerating voltage. Brie"y, 1 µL of nanoparticles was placed onto a 
400 mesh Cu grid with a carbon $lm support and excess liquid was 
blotted from beneath the grid and then le: to air dry. Images were 
captured using a bottom mounted Gatan Orius SC200 ccd camera with 
Digital Micrograph so:ware. #e magni$cations were calibrated using 
8.75nm lattice spacing of catalase crystals.
Di#erential scanning calorimetry
#e physical state of the pure drugs and the loaded MCM–
41 samples were examined by di*erential scanning calorimetry 
(DSC). #e thermographs of each powder were obtained by using a 
Mettler Toledo 823e (Greifensee, Switzerland) di*erential scanning 
calorimeter. Samples accurately weighted (2–3 mg) were placed in 
pierced aluminium pans and heated from 20 to 260°C at a scanning 
rate of 10°C min-1 in a nitrogen atmosphere.
Figure 1:$B(!'3-<"($:"-#+-3$7,$<!'$%*&'+(+"<"(-=$C*":$+'-(<7+@
(a)
(b)
Figure 2: (a–b) SEM micrographs of MCM–41 nanoparticles.
Figure 3: Particle size distribution of MCM – 41 nanoparticles using light 
scattering diffraction.
Citation: Patil A, Chirmade UN, Trivedi V, Lamprou DA, Urquhart A, Douroumis D (2011) Encapsulation of Water Insoluble Drugs in Mesoporous 
Silica Nanoparticles using Supercritical Carbon Dioxide. J Nanomedic Nanotechnol 2:111. doi:10.4172/2157-7439.1000111
Page 3 of 8
!"#$%&'(')'*++$&',')'-...---
J Nanomedic Nanotechnol
*//01(-23435,6'70809':;'"<&;':==&++'>"$?;:#
Atomic Force Microscopy (AFM)
For AFM experiments, 50 µL of silica particles which were 
suspended in toluene (99 %; Fisher Scienti$c, Loughborough, UK), was 
deposited onto a freshly cleaved mica surface (G250-2 Mica sheets 1” x 
1” x 0.006”; Agar Scienti$c Ltd, Essex, UK), and dried under ambient 
conditions for 5 h. #e images were obtained by scanning the mica 
surface in air under ambient conditions using a Veeco MultiMode 
with NanoScope 3D Controller Scanning Probe Microscope (Digital 
Instruments, Santa Barbara, CA, USA; Veeco so:ware Version 5.31r1) 
operated in tapping mode. #e AFM measurements were obtained using 
so: silicon probes (FESP; nominal length (l
nom
) = 225 µm, width (w
nom
) 
= 28 µm, tip radius (R
nom
) = 8 nm, resonant frequency (υ
nom
) = 75 kHz, 
spring constant (k
nom
) = 2.8 N m-1; Veeco Instruments SAS, Dourdan, 
France). AFM scans were taken at 512 x 512 pixels resolution and 
produced topographic images of the samples in which the brightness of 
features increases as a function of height. Typical scanning parameters 
were as follows: tapping frequency 71 kHz, integral and proportional 
gains 0.2 and 0.3, respectively, set point 0.7–1.0 V and scanning speed 
1.0 Hz. #ese experiments were repeated two times in fresh mica in 
6 di*erent areas. #e images were analyzed by using Veeco Image 
Analysis so:ware Version 6.14r1.
BET analysis
BET surface area, pore volume and pore diameter of MCM–
41 was measured by using Micromeritics Gemini 6 (Norcross, 
USA) automated gas sorption system model. #e determination of 
micropore volume, micropore surface area, and external surface area 
was estimated by using the standard t–plot calculations, while the pore 
size and distribution was estimated using Broekho* and de Boer (BdB) 
reports.
Dissolution studies
#e release of CBZ from loaded m-SiNPs samples carried out 
in 750 ml of 0.1 M hydrochloric acid for 2 hr using a Varian 705 DS 
dissolution paddle apparatus (Varian Inc. North Carolina, US) at 100 
rpm and 37 ± 0.5°C. A:er 2 hr operation, 250 ml of 0.20 M solution of 
trisodium phosphate dodecahydrate were added into the vessel (bu*er 
stage, PH 6.8) that has been equilibrated to 37C. At predetermined time 
intervals samples were withdrawn for HPLC assay. All dissolution 
studies were performed in triplicate.
HPLC Analysis
#e concentration of drug in the samples was determined by 
HPLC. An Agilent 1200 Series (Waldbronn, Germany) equipped with 
a multiple wavelength detector (MWD) and a Beckman - Coulter 
Nucleosil 100 RP, 5µm Χ 4.5 mm Χ 25 cm column was used for HPLC 
assay. Mobile phase contained ACN/water/phosphoric acid at a ratio 
of 49.9:49.9:0.2v/v. #e mobile phase was le: to stand for at least 12 
h. #e "ow rate was 1.0 mL min−1 and the injection volume was 20µL 
while column temperature maintained at 25°C. #e wavelength was 
monitored at 236 nm and calibration curves were constructed using 
standard solutions of known concentrations from 5µg/mL to 50µg/mL. 
#e Agilent so:ware calculated the peak area of each standard solution 
and sample automatically.
Cytotoxicity studies
Viability of intestinal Caco-2 cells was evaluated using MTT assay, 
which is associated to cell mitochondrial activity. #e assay is based 
on the ability of viable cells to convert thiazolyl blue tetrazolium 
bromide solution to the blue formazan crystals in their mitochondria 
(a)
(b)
Figure 4: (a – b) AFM images of MCM–41.
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[24]. Brie"y, the cells were seeded at a concentration of 5x104cells/mL/
well in 24-well plates and were incubated with silica nanoparticles at 
increasing concentrations for 1 day. #e cells in the $rst three wells 
were incubated in the absence of the formulation. DMSO (0.5 mL/well) 
was used as positive control for cell death.
A:er 24 hrs of incubation, 100 µL of MTT solution (concentration 
5 mg/mL) was added to the wells and incubated for two hours at 37°C. 
#e blue formazan salts were dissolved in 100 µL of acidi$ed isopropanol 
(0.33µL HCl in 100 mL isopropanol), which was transferred to 96-well 
plates and the absorbance was read on a microplate reader (Bio-Tec 
Instruments) at wavelength of 490 nm. Cell viability was calculated by 
comparing the number of viable cells in the formulation-treated wells 
to the non-formulation treated cells.
Results and Discussion
Silica synthesis and characterization
MCM–41 nanoparticles were prepared by the sol–gel process using 
CTAB as the structure directing agent similar to Huo et al. [2]. #e 
process carried out in alkaline media above the isoelectric point of silica 
where the silica precursors will be present as anionic species. As a result 
silica species precipitate and lead to intermediate mesophases through a 
(S+I-) route where S+ is the cationic surfactant and I- is the deprotonated 
Si–OH moiety. By altering the molar ratio of CTAB (1–2.5) and the 
processing times it is possible to control the obtained MCM–41 particle 
size and hence the surface area, the pore volume and the pore size (not 
shown). #e morphology of the produced nanoparticles was studied by 
SEM, AFM and TEM analysis. 
Figure 5: Transmission electron micrograph of MCM–41 nanoparticles.
Figure 6: X – ray diffractogram of pure MCM–41 nanoparticles synthesized by 
the sol – gel process.
Figure 7: Nitrogen adsorption isotherm for synthesized MCM–41. The inset 
image shows the pore size distribution.
(a)
(b)
Figure 8: XRD patterns of a) CBZ loaded MCM – 41 nanoparticles process by 
acetone, ethanol – pure CBZ     (bottom) and b) methanol and control (processed 
only with CO
2
).
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In Figure 2 the SEM micrographs displayed relatively uniform 
particle size distribution of approximately 200nm with a spherical 
shape. It can be seen that particles are almost spherical with a rough 
surface. #e particle size was accurately estimated by dynamic light 
scattering measurements (Figure 3) and it was found to be 186nm 
(polydispersity index 0.522). #e particle size distribution could be an 
issued for the synthesis of MCM-41 nanoparticles as they present high 
poyldispersity index. Nevertheless, there are reports where synthesized 
silica nanoparticles demonstrated narrow particle size distributions 
[25]. In our case the obtained particle size was reproducible under 
the conditions followed for the MCM-41 synthesis. In addition, 
nanoparticles were further characterized by atomic force microscopy 
studies [26] to image the shape and the appearance of pure MCM–41. 
As shown in Figure 4 (a,b) AFM can e&ciently resolve surface details 
in the nanometer scale by producing three dimensional images of 
the MSN samples. #e MCM–41 can be clearly seen as spherical 
particles with 200 nm diameter, very high homogeneity and smooth 
surface. In addition, the TEM image depicted in Figure 5 show a 
honeycomb porous structure which is the result of hexagonal packing 
of unidimentional cylindrical pores. #e ordered hexagonal array was 
further con$rmed by the X–ray di*ractogram shown in Figure 6 with 
four Bragg re"ections that can be indexed as (100), (110), (200) and 
(210) typical of hexagonal p6mm con$guration. #e intense re"ection 
that corresponds to the (100) di*raction peak with d = 45.5A° gives a 
lattice constant (pore centre distance) of α
o
 = 52.5A°estimated by the 
hexagonal unit cell relation (α
o
 = 2d
100
/ 3). 
#e speci$c surface area estimated with the standard BET method 
was 980m2g-1 with a measured mesoporous volume of 0.65cm3g-1 and a 
narrow pore size distribution centred at 2.9nm. As depicted in Figure 
7 the nitrogen–adsorption of the prepared MCM–41 is a typical IV– 
isotherm of mesoporous materials with a step in the range of P/P
o
 = 
(a)
(b)
Figure 9: DSC thermograms of a) CBZ loaded MCM – 41 nanoparticles process by acetone, methanol – pure CBZ (bottom) and b) ethanol and control (processed only 
with CO
2
).
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0.3–0.4 which is typical for the $lling of mesoporous systems. #e 
thickness of the pore wall can be estimated by the di*erence between 
the pore centre distance and the pore diameter. #e estimated wall 
thickness [12] can be estimated from the di*erence the pore distance 
and the mean mesopore width (d
pore wall
 = a
0
 – W
BJH
) and it was found 
2.4nm.
Carbamazepine inclusion into MCM–41 
#e synthesized MCM–41 nanoparticles presented high speci$c 
surface area and pore volume in order to achieve the highest possible 
drug loading [6]. #e tree main methods reported for the drug 
inclusion in mesoporous silica nanoparticles are the solvent method, 
the impregnation method and the melt method [23]. In the current 
study we report for $rst time the use of supercritical CO
2
 for the 
inclusion of active substances within the silica pores. #e employment 
of supercritical "uids is advantageous compared to the previous 
methods because it is one step process, facilitates high drug loading, 
removes un–trapped drug during depressurization and loaded silica 
nanoparticles are obtained in a powder form. 
Carbamazepine was dissolved in acetone or methanol prior 
supercritical "uid processing. #e selection of the solvents was based 
on previous studies [5] where CBZ showed high dissolving capacity 
within these solvents. #e SF loading parameters were kept unchanged 
in order to investigate the solvent e*ect on CBZ encapsulation and the 
obtained crystalline state. 
During the loading process the active molecules di*use in the 
MCM–41 channel pores and onto the outer surface. As mentioned 
above the pore size of the MCM–41 is approximately 3nm and large 
enough to host the loaded material. #e SF loading process revealed 
substantial drug loading (DL) e&ciency (Table 2) for all solvents 
varying from 27–33% in descending order EtOH>ACT>MeOH. 
Physicochemical characterisation 
#e produced CBZ/MCM–41 loaded powders were fully 
characterized by X–ray and DSC studies in order to determine CBZ 
crystalline state within the pore channels. It is known that CBZ 
polymorphs can be obtained upon crystallization from various 
solvent [27]. #us, it is important to investigate the in"uence of the 
solvents on the CBZ crystal habits. #e intensity peak positions and 
the relative intensities of pure CBZ and loaded samples are shown in 
Table 1. As it can also be seen from Figure 8 (a, b) the di*ractogram 
of pure CBZ corresponds to form III (P–monoclinic) and they are 
in a good agreement with the results published by Rustichelli et al. 
[28]. Similarly the X–ray di*ractograms of the samples processed 
with EtOH>MeOH>ACT correspond to form III>form II>form III 
respectively. However, the intensities of the measured samples vary, 
especially for forms I and II, compared to previous studies [28,29] 
Figure 10:$ D"%%7=*<"76$ &+7)='%$ 7,$ EFG$ =7-:':$ HEH$ I$ J>$ 6-67&-+<"(='%$
&+7('%%':$KL$'<!-67=$.M5N$-('<76'$.O) and methanol (P), (n = 3).
Figure 11: Dose-dependent toxicity of silica nanoparticles on Caco-2 cells 
treated with various concentrations of MCM–41 nanoparticles for 24 h. Cell 
viability was determined by MTT assay. Control cells cultured in absence of 
nanoparticles in parallel to the treated groups. Values were the mean ± SD from 
three independent experiments.
*CBZ/CO
2
(Form I)
**CBZ/MeOH
(Form II)
**CBZ/ACT
(Form III)
CBZ pure
(Form III)
2!
Intensity 
(%)
2!
Intensity 
(%)
2!
Intensity 
(%)
2!
Intensity 
(%)
10.10 4.47 5.02 100 5.00 35.51 12.69 21.35
>Q@21 0>@1Q 1@?? 35.25 1@?? >1@RS 13.00 J1@>R
13.65 25.77 12.25 ?1@?> >Q@21 100 >Q@S1 100
14.16 27.39 13.23 9.70 13.33 24.60 14.10 30.02
15.04 100 >1@Q1 12.42 14.14 T1@Q2 14.94 J1@T?
15.29 0J@S1 20.10 J?@T1 >J@01 JT@J1 15.30 90.56
>S@1T 52.65 24.40 19.70 15.27 1S@SS >S@R1 59.16
>1@?0 40.56 >S@1Q 52.25 >1@S? 30.10
19.55 50.34 >1@?R 35.20 19.36 51.21
20.34 23.90 19.46 J1@>2 20.29 T0@Q1
23.36 22.44 20.05 26.40 23.35 29.21
TQ@1R 29.19 23.34 22.00 TQ@1R Q0@Q1
24.94 44.97 TQ@1S Q2@R1 24.75 33.40
26.65 23.31 24.90 37.55 27.49 1S@11
27.19 Q0@12 26.67 30.74
27.54 39.75 27.60 47.01
*sample processed with only CO
2
 (control), **samples processed with CO
2
 and 
various solvents
Table 1: Powder X-ray Diffraction peak positions and relative intensities of the 
anhydrous polymorphs of CBZ produced after supercritical processing with various 
organic solvents.
Table 2: Transition Temperatures, enthalpy of melting, and drug loading of CBZ 
samples.
Samples Peak 1 (oC) Peak 2 (oC) Peak 3 (oC) UV$.W#-1) Loading (%)
Control (CO
2
) - - 191.75 -92.46 -
CBZ pure - >??@1S 190.72 X1R@?R -
CBZ/ACT - 160.34 191.16 -77.55 31.5
EFG4H'YV - - 191.09 X>22@11 27.4
EFG4Z<YV 99.90 164.92 191.00 X?Q@1Q 33.2
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because of the preferred orientations of samples in the powder X–ray 
analysis. 
Figure 9 (a, b) shows the DSC thermograms of pure CBZ and 
MCM – 41 loaded samples. Previous studies demonstrated that CBZ 
exhibits enantiotropic polymorphism, which means a transition 
temperature can be observed below the melting point of either of the 
polymorphs at which both these forms have the same free energy. 
Above the transition temperature, the higher melting form (I) has the 
lower free energy and is more stable. According to other researchers 
[27,28] the DSC thermograms of CBZ form III shows two endotherms 
where the $rst endotherm is present in the range 160–175°C and is not 
followed by any exothermic event while a sharp endotherm occurs at 
the range 189–192°C. #e thermogram of pure CBZ showed a small 
melting endotherm at 166.67°C followed by a second endotherm at 
191.67°C. #ese two endotherms correspond to form III and I of CBZ, 
respectively. #e melting endotherm at 191.67°C indicates that the 
used CBZ herein was form III. 
Interestingly, CBZ/MCM – 41 samples processed with ACT or 
EtOH showed the presence of CBZ form III and I respectively (Table 
2). #e CBZ form I have been reported before [28] and show a single 
endothermic peak approximately at 192°C. In contrast, samples 
processed with EtOH showed an exothermic peak at 99.90°C followed 
by a melting endotherm at 191.67°C that corresponds to the trigonal 
form II. #e presence of the exothermic peak in the range of 80 – 100oC 
is typical for CBZ polymorph II due to the presence of amorphous 
sample crystalling during DSC [28]. #e DSC traces and also the melting 
points depend on the heating rates and thus they could be slightly 
di*erent to those reported in literature. It is obvious that the nature of 
the solvent used in combination to super CO
2
 a*ects CBZ crystalline 
state. #e in"uence of CO
2
 was also investigated by processing equal 
amounts of CBZ powder under the same experimental settings. #e 
results indicate that the obtained CBZ powder was in form I as shown 
in Figure 9b. It is obvious that CO
2
 can alter CBZ crystal habit. #e DSC 
thermograms are in agreement with the X–ray studies and con$rm the 
previous observations. In conclusion, the above studies showed that 
solvents play a key role on the crystalline state of polymorphic active 
substances when co-processed with supercritical CO
2
.
Dissolution studies 
#e dissolution pro$les of CBZ/MCM - 41 loaded nanoparticles 
were investigated under sink conditions (C<0.2 Cs). As shown in 
Figure 10 all samples demonstrated increased CBZ dissolution 
pro$les with more than 65% of the active been released a:er 60 min. 
#e release percentage where found to depend on the actual drug 
loading. As it can be seen in Figure 8 the MCM–41 nanoparticles 
with the higher CBZ loading demonstrated faster dissolution rates. 
#e encapsulation of water insoluble drugs within the pore channels 
of silica nanoparticles facilitated e&cient drug particle size reduction 
and hence improved dissolution rates. As mentioned above the 
average pore diameter is approximately 2.9 nm which means that the 
particle size of the encapsulated CBZ is smaller than the pore diameter. 
In addition, the rapid dissolution pro$les can be explained by the 
displacement desorption of CBZ by the in"ux of water [30]. In this 
case the encapsulated CBZ is desorbed by competitive adsorption of 
water molecules on the hydrophilic silica surface. We also assumed 
that CBZ did not interact with silanol groups that could retard the 
drug dissolution as it has been previously reported [31]. #e increased 
dissolution pro$les and the CBZ loading e&ciency are of particular 
interest for pharmaceutical applications in order to improve the 
delivery of poorly soluble drugs and consequently increasing drug 
absorption and bioavailability. For Class II active substances the 
dissolution rate is the limiting factor to adsorption.
Cell cytotoxicity
In the last decade, silica nanoparticles have been widely used for 
various biopharmaceutical applications and in many occasions have 
been found to induce cytotoxicity in cell culture lines [32].In these 
studies it was demonstrated that cell cytotoxicity depends on the actual 
particle size of the silica nanoparticles. In our studies we conducted 
MTT cytotoxicity assays using Caco–2 cells. As it is can be seen in 
Figure 11 the MCM–41 demonstrated relatively low cytotoxicity and at 
high concentrations (15mg/ml) cell viability was above 75%. Although 
additional studies are required to prove the safety of MCM – 41, recent 
studies [33] showed that low in vitro cytoxicity is a good indication 
for in vivo biocompatibility. As a result MCM–41 nanoparticles could 
be e*ectively used asa drug delivery systems for oral administration of 
active substances. 
Conclusions 
In the current study we synthesized MCM–41 nanoparticles with 
high surface area and narrow pore size for the encapsulation of a major 
antiepileptic active substance. #e encapsulation was carried out by 
implementing supercritical CO
2
 process in combination with various 
solvents. #e results demonstrated that SF processing increased drug 
loading while drug encapsulation in silica nanoparticles enhanced 
dissolution rates. It was also demonstrated that co–processing with 
various solvents in"uences CBZ crystalline state depending on the 
solvent nature. #e MTT assay studies of Caco–2 cells indicated 
low cytotoxicity at high MCM–41 nanoparticle concentrations. In 
conclusion, SF can be successfully employed for the delivery of active 
substances using MCM–41 nanoparticles. 
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